Kite Pharma, Inc.
KITE
KITE was delisted on the 2nd of October, 2017.
0 hedge funds and large institutions have $0 invested in Kite Pharma, Inc. in 2017 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 241 closing their positions.
86.09% less ownership
Funds ownership: 86.09% → 0% (-86%)
100% less funds holding
Funds holding: 244 → 0 (-244)
100% less funds holding in top 10
Funds holding in top 10: 23 → 0 (-23)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $8.87B
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 241
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Cowen Inc
New York
|
-$755M |
| 2 |
BlackRock
New York
|
-$744M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$736M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$483M |
| 5 |
WCM
Wildcat Capital Management
New York
|
-$433M |
KITE Hedge Fund Activity: Q4 2017 in Review
0 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q4 2017, worth a combined $0 — down 100% from $8.88B a quarter earlier.
Sellers outnumbered buyers: 241 funds closed out of KITE and 0 opened new positions — a net loss of 241 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Cowen Inc, exiting entirely with an estimated $755M sold.
- 0 institutional investors held Kite Pharma, Inc. (KITE) as of Q4 2017, down from 244 in Q3 2017.
- Funds reported $0 of Kite Pharma, Inc. stock for Q4 2017, down 100% quarter-over-quarter.
- 0 funds opened new Kite Pharma, Inc. positions in Q4 2017 and 241 closed out, a net change of -241 holders.
- The largest Kite Pharma, Inc. seller in Q4 2017 was Cowen Inc, an estimated $755M sold.
Based on aggregated 13F filings for Q4 2017.